Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

Heinz Ludwig,David Samuel Dicapua Siegel,Meletios A Dimopoulos,Roman Hajek,Aleksandr Suvorov,Philippe Moreau,Albert Oriol Rocafiguera,Laura Rosinol,Sanjay Aggarwal,Tamas Masszi,Georgi Mihaylov,Vesselina Goranova-Marinova,Jesus San Miguel,Ruben Niesvizky,Ivan Spicka,Mihaela Obreja,Antonio Palumbo,Andrzej J Jakubowiak,Peter Rajnics

doi:10.1200/jco.2016.34.15_suppl.8045

Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

Heinz Ludwig, David Samuel Dicapua Siegel + Show 17 more

https://doi.org/10.1200/jco.2016.34.15_suppl.8045

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2016
Citations: 3

Affiliation: Wilhelminen Hospital, Hackensack University Medical Center, National and Kapodistrian University of Athens, University of Ostrava, The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic, Hôtel-Dieu de Paris, Hospital Universitari Germans Trias i Pujol, Amgen (United States), National Specialized Hospital for Active Treatment of Hematologic Diseases, University of Navarra, University of Turin, University of Chicago Medical Center

#Relapsed Multiple Myeloma #Improvement In Median Progression-free Survival + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

8045Background: The randomized phase 3 ASPIRE trial demonstrated an improvement in median progression-free survival (PFS) for KRd compared with Rd in patients with RMM (26.3 months vs 17.6 months, ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.